Knockdown of FATP4 or CPT1A markedly increased the susceptibility of NSCLC cells to osimertinib and gefitinib, according to subsequent CCK-8, colony formation experiments and flow cytometry (Fig. 6C-E). Here, CPT1A is linked to non-small cell lung carcinoma.